v3.26.1
Segment information (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Financial Data for the Company's Reportable Segment

The following table presents certain financial data for the Company’s reportable segment, including significant segment expenses regularly provided to the chief operating decision maker to assess performance of the Company.

 

 

 

Three Months Ended
March 31,

 

 

2026

 

 

2025

 

 

($'000)

 

 

($'000)

 

Research and development expenses

 

 

 

 

 

 

Setrusumab (BPS-804/UX143)

 

$

(4,052

)

 

$

(2,244

)

Alvelestat (MPH-966)

 

 

(443

)

 

 

(1,365

)

Etigilimab (MPH-313)

 

 

(194

)

 

 

(207

)

Other

 

 

(58

)

 

 

(114

)

General and administrative expenses

 

 

(4,019

)

 

 

(7,272

)

Other segment items

 

 

2,047

 

 

 

(1,685

)

Net loss before income tax

 

$

(6,719

)

 

$

(12,887

)